Journal of Neuro-Oncology

, Volume 89, Issue 2, pp 187–193

A phase II study of intensified chemotherapy alone as initial treatment for newly diagnosed anaplastic oligodendroglioma: an interim analysis

  • Nimish A. Mohile
  • Peter Forsyth
  • Douglas Stewart
  • Jeffrey J. Raizer
  • Nina Paleologos
  • Tarun Kewalramani
  • David N. Louis
  • J. Gregory Cairncross
  • Lauren E. Abrey
Clinical-patient studies


Background Anaplastic oligodendrogliomas (AO) and anaplastic oligoastrocytomas (AOA) are currently treated with a combination of surgery, radiotherapy and chemotherapy. Myeloablative therapy with autologous peripheral blood progenitor cell rescue (APBPCR) is one strategy to exploit the chemosensitivity of these tumors while deferring cranial radiation in an effort to avoid radiation-related neurotoxicity. Methods Twenty patients (16 AO, 4 AOA) with a median age of 46 years (range, 19–60) and KPS of 90 (range, 70–100) were treated with 4 cycles of procarbazine, Lomustine (CCNU) and vincristine (I-PCV) every six weeks. Responding patients were eligible for myeloablative therapy with busulfan and thiotepa followed by APBPCR. 1p and 19q chromosomes were analyzed prospectively but patients were enrolled without regard to deletion status. Results Fifteen patients (75%) had a response to I-PCV and 14 underwent transplant. Median disease-free and overall survival of the transplanted patients has not been reached but is at least 36 months. No patients required dose reduction or termination of I-PCV due to toxicity. Hepatic veno-occlusive disease (VOD) was a complication of transplant in three patients and resulted in one death. Patients with and without deletions of 1p and 19q had durable responses. Conclusions This regimen conferred durable responses in more than one-half of patients, allowing deferral of radiotherapy for three years or longer. The major limitation of this approach is the acute toxicity associated with both the induction and consolidation regimens; temozolomide has replaced I-PCV for the current trial and the incidence and severity of VOD is being followed closely.


Anaplastic oligodendroglioma Chemotherapy 1p 19q Procarbazine 


  1. 1.
    Cairncross G, Macdonald D, Ludwin S et al (1994) Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 12:2013–2021PubMedGoogle Scholar
  2. 2.
    Cairncross G, Berkey B, Shaw E et al (2006) Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24:2707–2714PubMedCrossRefGoogle Scholar
  3. 3.
    van den Bent MJ, Carpentier AF, Brandes AA et al (2006) Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 24:2715–2722PubMedCrossRefGoogle Scholar
  4. 4.
    Crossen JR, Garwood D, Glatstein E, Neuwelt EA (1994) Neurobehavioral sequelae of cranial irradiation in adults: a review of radiation-induced encephalopathy. J Clin Oncol 12:627–642PubMedGoogle Scholar
  5. 5.
    Paleologos NA, Macdonald DR, Vick NA, Cairncross JG (1999) Neoadjuvant procarbazine, CCNU, and vincristine for anaplastic and aggressive oligodendroglioma. Neurology 53:1141–1143PubMedGoogle Scholar
  6. 6.
    Abrey LE, Childs BH, Paleologos N et al (2003) High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma. J Neurooncol 65:127–134PubMedCrossRefGoogle Scholar
  7. 7.
    Abrey LE, Childs BH, Paleologos N et al (2006) High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: long-term follow-up. Neuro Oncol 8:183–188PubMedCrossRefGoogle Scholar
  8. 8.
    Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) (2007) World Health Organization International Agency for Research on Cancer.Google Scholar
  9. 9.
    Macdonald DR, Cascino TL, Schold SC, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277–1280PubMedGoogle Scholar
  10. 10.
    Stupp R, Mason WP, Van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996PubMedCrossRefGoogle Scholar
  11. 11.
    Abrey LE, Louis DN, Paleologos N et al (2007) Survey of treatment recommendations for anaplastic oligodendroglioma. Neuro-Oncol 9:314–318PubMedCrossRefGoogle Scholar
  12. 12.
    Careras E, Bertz H, Arcese W et al (1998) Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. Blood 92(10):3599–3604Google Scholar
  13. 13.
    Ridola V, Grill J, Doz F et al (2007) High-dose chemotherapy with autologous stem cell rescue followed by posterior fossa irradiation for local medulloblastoma recurrence of progression after conventional chemotherapy. Cancer 110:156–163PubMedCrossRefGoogle Scholar
  14. 14.
    Jenkins RB, Blair H, Ballman KV et al (2006) a t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 66(20):9852–9861PubMedCrossRefGoogle Scholar
  15. 15.
    Ino Y, Betensky RA, Zlatescu MC et al (2001) Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res 7:839–845PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2008

Authors and Affiliations

  • Nimish A. Mohile
    • 1
  • Peter Forsyth
    • 2
  • Douglas Stewart
    • 2
  • Jeffrey J. Raizer
    • 3
  • Nina Paleologos
    • 4
  • Tarun Kewalramani
    • 5
  • David N. Louis
    • 6
  • J. Gregory Cairncross
    • 7
  • Lauren E. Abrey
    • 1
  1. 1.Department of NeurologyMemorial Sloan-Kettering Cancer CenterNew YorkUSA
  2. 2.Tom Baker Cancer CenterUniversity of CalgaryCalgaryCanada
  3. 3.Northwestern University, Feinberg School of MedicineChicagoUSA
  4. 4.Northwestern UniversityEvanstonUSA
  5. 5.Department of MedicineMemorial Sloan-Kettering Cancer CenterNew YorkUSA
  6. 6.Massachusetts General Hospital and Harvard Medical SchoolBostonUSA
  7. 7.University of CalgaryCalgaryCanada

Personalised recommendations